Joleen Hubbard, MD, Mayo Clinic

Articles

Best Practices Surrounding IO Treatment for mCRC

May 14th 2021

Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.

Frontline I-O Treatment for mCRC

May 14th 2021

Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.

Biomarker Testing and Precision Medicine in mCRC

May 7th 2021

A panel of gastrointestinal oncologists discuss current options for molecular testing based on the understanding that predictive biomarkers play a role in the management of metastatic colon cancer.

Fruquintinib for Refractory mCRC

May 7th 2021

Expectations regarding the use of fruquintinib, an oral VEGF tyrosine kinase inhibitor, as third-line therapy for metastatic colorectal cancer.

Best Strategies for Sequencing Regorafenib in mCRC

April 30th 2021

Considerations for how to sequence therapy with regorafenib for relapsed or refractory metastatic colorectal cancer based on the REVERCE II study.

TAS-102 for Refractory mCRC

April 30th 2021

Variables that impact patient selection for TAS-102 treatment as later-line therapy for metastatic colorectal cancer and considerations for using TAS-102 in combination with bevacizumab.

Regorafenib as Later-Line Treatment for mCRC

April 23rd 2021

The rationale for treating metastatic colon cancer with regorafenib in a later-line setting and the importance of applying the dose-escalation strategy demonstrated by the ReDOS trial into clinical practice.

BRAF-Mutated mCRC: Treating With the BEACON Regimen

April 23rd 2021

Gastrointestinal oncologists consider when it is most appropriate to initiate the BEACON trial regimen of encorafenib-binimetinib-cetuximab as treatment for BRAF-mutated metastatic colorectal cancer.

Treatments for BRAF-Mutated mCRC

April 16th 2021

Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.

Second-Line Treatment of mCRC: Rechallenging Therapy

April 16th 2021

The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.

Preferences for Second-Line Therapy for mCRC

April 9th 2021

Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.

Maintenance Therapy for Metastatic CRC

April 9th 2021

Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.

Applying Aggressive Therapy to Treat mCRC Up Front

April 2nd 2021

The rationale for treating select patients with metastatic colorectal cancer with intensive therapy in the first-line setting vs waiting until disease progression.

Colorectal Cancer in a Younger Population

April 2nd 2021

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.

Optimizing mCRC Treatment: Decision-Making With Patients

March 25th 2021

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Initial Strategies for Assessing and Treating mCRC

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.

Dr. Hubbard on Detecting Disease Progression in CRC

February 23rd 2021

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.

Dr. Hubbard on Sequencing Challenges With EGFR Inhibitors in CRC

January 22nd 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.